Medicare Decision Forces ExonHit to Cancel RedPath Acquisition

ExonHit stressed it is not out of the M&A game, saying it "is committed to pursuing its strategy of development via external growth and maintains its objective to acquire a revenue-generating molecular diagnostic company."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.